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Introduction: Available literature suggests that the advantage of animal-derived surfactants 
over ﬁ  rst-generation synthetic agents derives from the presence of surface-active proteins and 
their phospholipid content. Here we summarize the results of clinical trials comparing animal-
derived surfactant preparations with other animal-derived surfactants and with both ﬁ  rst- and 
second-generation synthetic surfactants.
Methods: Published clinical trials of comparisons of animal-derived surfactants were sum-
marized and compared. Comparisons emphasized differences in (1) key surfactant components 
attributed with efﬁ  cacy and (2) differences in published outcomes.
Results: For the most important outcomes, mortality and chronic lung disease, currently avail-
able natural surfactants are essentially similar in efﬁ  cacy. When examining secondary outcomes 
(pneumothorax, ventilator weaning, and need for supplemental oxygen), it appears that both 
calfactant and poractant have an advantage over beractant. The weight of the evidence, especially 
for study design and secondary outcomes, favors the use of calfactant. However, the superiority 
of poractant over beractant, when the higher initial dose of poractant is used, strengthens the 
case for use of poractant as well.
Conclusions: Clinical trials suggest that the higher surfactant protein-B content in calfactant, 
and perhaps the higher phospholipid content in poractant (at higher initial dose), are the factors 
that most likely confer the observed advantage over other surfactant preparations.
Keywords: surfactant, respiratory distress syndrome, phospholipids, surfactant proteins, chronic 
lung disease, bronchopulmonary dysplasia
Background
The lungs of premature infants born between 23 and 32 weeks gestation are in the 
saccular stage of development.1 The available surfactant pool in the gas exchange units 
is decreased or absent at this stage of development, and this deﬁ  ciency in surfactant 
results in increased surface tension and the inability to maintain expansion of the 
terminal lung units at end-expiration (low lung volumes on chest radiograph). These 
anatomic and biochemical derangements are accompanied by a decrease in the surface 
area available for gas exchange and an increase in the diffusion distance required for 
oxygen to cross the lung-capillary interface. These derangements were responsible 
for the relatively high respiratory distress syndrome (RDS)-related mortality of the 
pre-surfactant era. Mechanical ventilation with high distending pressures, aimed 
at overcoming the physiologic consequences of surfactant deﬁ  ciency, resulted in 
irreversible ventilator-induced lung injury and mortality in a signiﬁ  cant proportion 
of infants with RDS.
Use of exogenous surfactant has resulted in a signiﬁ  cant reduction in morbidity 
and mortality.2–4 Several reports suggest that animal-derived surfactants appear to have Therapeutics and Clinical Risk Management 2009:5 252
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physical properties that are superior to synthetic surfactants.5 
These physical properties translate into improvements in 
physiologic measures of lung function when compared 
to ﬁ  rst-generation synthetic surfactants.6 Earlier synthetic 
surfactant preparations, ie, colfosceril palmitate (Exosurf®) 
and pumactant (ALEC®), included key phospholipids, 
predominantly dipalmitoyl-phosphatidylcholine (DPPC), but 
lacked essential surfactant proteins. These surfactant proteins, 
especially surfactant protein B (SP-B) and surfactant protein 
C (SP-C), are essential biophysical components of pulmonary 
surfactant. The absence of SP-B leads to fatal lung disease 
in full-term newborn infants.7,8 These proteins appear to 
promote important physical functions at the air–phospholipid 
interface, including improved surface-tension reduction and 
stabilization of the phospholipid monolayer.9,10 Surfactant 
protein A (SP-A) and surfactant protein D (SP-D) play an 
important role in immune defense and metabolism, but do 
not play a signiﬁ  cant role in stabilizing the alveoli as do 
SP-B and SP-C.10
Here we summarize published clinical trials of comparisons 
of animal-derived surfactants with other animal-derived 
surfactants and both ﬁ  rst- and second-generation synthetic 
surfactants. The quality of included studies is based largely 
on the quality assessment used in a recently published review 
by the senior author, which evaluated studies based on blind-
ing, randomization, withdrawals, and “intention-to-treat 
analysis.11,12 Studies with a quality score of 5 were deemed 
‘rigorous’, those with a quality score of 3 or 4 were deemed 
‘moderately rigorous’, and those with a quality score of 2 or 
less were considered ‘less rigorous’.
Differences in currently available 
animal-derived surfactants (Table 1)
Animal-derived surfactants are derived from bovine or porcine 
lung minces or lung lavages, which are subsequently puriﬁ  ed 
and extracted with organic solvents. The resulting preparation 
includes predominantly phospholipids, neutral lipids and 
low molecular weight, hydrophobic SP-B and SP-C. SP-A 
and SP-D are extremely hydrophilic, and are not present 
to any appreciable degree in currently available animal-
derived surfactants.13 Poractant, also known as Curosurf® 
(Chiesi Farmaceutici, Prima, Italy), is prepared from washed, 
centrifuged extract of minced porcine lungs, which undergoes 
an additional puriﬁ  cation that removes neutral lipids from the 
extract.9 The bovine minced lung extract beractant, also known 
as Survanta® (Abbott Laboratories, Columbus, OH, USA), 
includes the addition of DPPC, palmitic acid, and tripalmitin.9 
Calfactant, also known as Infasurf® (Forest Pharmaceutical, 
St Louis, MO, USA), is derived from broncho-alveolar lavage 
of calf lungs, and reportedly has a higher concentration 
of SP-B than either of the minced lung preparations. 
Presumably, the concentration of SP-B is lower in 
minced lung preparations due to processing.9,14 Alveofact® 
(Boehringer Ingelheim, Ingelheim Germany), which is no 
longer available commercially, was derived from bovine 
broncho-alveolar lung lavage and reportedly had a higher 
concentration of SP-B than beractant. The phospholipid 
concentration in all animal-derived surfactant preparations 
may be variable between lots. However, poractant has the 
highest (80 mg/mL) per unit concentration among available 
animal-derived surfactant preparations and also the highest 
phospholipid dose (200 mg/kg), when the high (initial) dose 
of phospholipids is used (Table 1).11
While animal-derived surfactants have physiologic 
advantages, including the presence of surface active proteins 
that enhance the adsorption and stability of the phospholipid 
monolayer, they also have several disadvantages, including 
the potential for immunogenicity and for transmitting 
animal-borne infectious agents.15 There is some concern that 
animal-derived surfactants may have batch-to-batch variation 
in levels of native surfactant proteins.10,13 Animal-derived 
surfactants may also contain pro-inﬂ  ammatory mediators, 
which have been linked with respiratory diseases in animals 
and humans.10,16 To date these concerns remain theoretical as 
clinical trials have not supported the association of animal-
derived surfactants with long-term sequelae, although 
long-term follow-up is lacking for most of the clinical trials 
comparing surfactant preparations.
Animal-derived surfactants 
for treatment (rescue) of RDS 
(comparisons of animal-derived 
surfactants vs other animal-derived 
surfactants)
Beractant vs calfactant
Bloom 1997: This trial was conducted between 1992 and 
1993, and included both a treatment arm and a prevention 
arm. The treatment arm included 608 infants whose 
birthweight (BW) was 2000 g, and while only 10% of 
participants were exposed to antenatal steroids, the trial 
was rigorous in study design. Outcome measures included 
mortality at discharge and the proportion of infants in 
oxygen at 36 weeks corrected gestational age (CGA). Faster 
weaning from mechanical ventilation and fewer repeat doses 
of surfactant were reported in the calfactant group, but Therapeutics and Clinical Risk Management 2009:5 253
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there were no signiﬁ  cant differences in overall mortality or 
neonatal morbidities, including pneumothorax.17
Attar 2004: This small (n = 40), single center study 
included infants 37 weeks gestation, and used a less 
rigorous study design, but at least 79% of study participants 
were exposed to antenatal steroids. Reported outcomes 
included mortality at discharge, the proportion of infants in 
oxygen at 36 weeks CGA, and pulmonary compliance. The 
calfactant group weaned from mechanical ventilation sooner 
and required fewer doses of surfactant than the beractant 
group, but there were no differences in study outcomes.18
Bloom and Clark 2005: This publication reported 
the outcomes of two trials, conducted between 2001 and 
2003, and used a rigorous study design, including ‘intention-
to-treat’ analyses. At least 73% of participants were exposed 
to antenatal steroids. 1361 infants whose BW was between 
401 and 2000 g were included in analyses, and the outcomes 
measured were mortality at discharge and proportion 
of infants in supplemental oxygen at 36 weeks. Faster 
weaning from both mechanical ventilation and supplemental 
oxygen and a non-signiﬁ  cant reduction in the incidence of 
pneumothorax was noted in the calfactant group.19
Clinical trials comparing beractant with calfactant suggest 
that when used for treatment, calfactant has a signiﬁ  cant 
advantage in short-term outcomes, but no advantage with 
regard to mortality or oxygen requirement at 36 weeks. 
While calfactant has a higher phospholipid concentration per 
unit volume than beractant, the total dose of phospholipid 
is similar. Thus, the short-term advantages of calfactant are 
presumably mediated, at least in part, by its higher SP-B 
concentration (Table 2).17–19
Beractant vs alveofact
Baroutis 2003: This small (n = 80), single-center study 
randomized patients to receive beractant, alveofact or porac-
tant for treatment of RDS, and included infants 32 weeks 
gestation whose BW was 2000 g. The study design was 
less rigorous, and less than 35% of participants were exposed 
to antenatal steroids. The beractant group received dosing 
via a side-port adapter at slow infusion rate, which may 
have affected the delivery of surfactant. Study outcomes 
included mortality at discharge and the proportion of infants 
in oxygen at 36 weeks. There were no differences in primary 
outcomes.20
Hammoud 2004: This small single-center study included 
109 infants 34 weeks gestation. The study was moder-
ately rigorous in design and approximately 50% of partici-
pants were exposed to antenatal steroids. Study outcomes 
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included mortality, chronic lung disease (CLD) at 28 days, 
and pneumothorax. There were no differences in mortality 
or pneumothorax, but contrary to the ﬁ  ndings of Baroutis 
et al the beractant group appeared to wean from respiratory 
support quicker and had a lower incidence of CLD.21
Yalaz 2004: This small, single-center study included 
50 infants 36 weeks gestation with clinical RDS. The 
study design was less rigorous than some but at least 64% of 
study participants were exposed to antenatal steroids. Study 
outcomes included mortality at 28 days, CLD at 36 weeks, 
and pneumothorax. There were no differences in morbidity 
and mortality between the two groups.22
Clinical trials comparing beractant with alveofact 
demonstrate no clear advantage of one surfactant over the 
other for the treatment of RDS. While alveofact contains 
more SP-B than beractant, and would in theory offer some 
advantage over beractant, the phospholipid dose in alveofact 
is lower (50 mg/kg) than that found in beractant (100 mg/kg) 
(Table 1). One explanation for the relative equivalence of 
these preparations is that the advantages of higher SP-B 
content in alveofact may have been balanced by the higher 
dose of phospholipid found in beractant (Table 2).20–22
Poractant vs beractant
Speer 1995: This small (n = 73), multicenter trial, conducted 
between 1991 and 1992, included infants whose BW was 
between 700 and 1500 g. The study was less rigorous in 
design and only about 40% of study participants were exposed 
to antenatal steroids. The treatment regimen included a high 
(200 mg/kg) initial dose of poractant (based on the dose of 
phospholipid). Study outcomes included mortality at 28 days, 
CLD at 36 weeks, and incidence of pneumothorax. Infants 
in the poractant group required less ventilatory support and 
oxygen during the ﬁ  rst 24 hours after treatment, but there 
was no signiﬁ  cant difference in duration of mechanical 
ventilation, need for supplemental oxygen, or primary 
outcomes at ﬁ  nal analysis.23
Baroutis 2003: This single-center study included 53 
randomized infants 32 weeks gestation and 2000 g, to 
receive beractant, alveofact or poractant for treatment of 
RDS. The study design was less rigorous and less than 35% 
of participants were exposed to antenatal steroids. While 
the initial dose of phospholipid in the Speer et al trial was 
200 mg/kg in the poractant group, the initial dose in this 
trial was equivalent between groups at 100 mg/kg. Study 
outcomes included were mortality at discharge, the proportion 
of infants in oxygen at 36 weeks, and air leaks. There were 
no differences in major outcomes, but less respiratory support 
was needed in the group receiving poractant.20
Ramanathan 2004: This moderately sized (n = 293), 
multicenter trial, conducted between 2000 and 2001, 
included infants 35 weeks gestation and between 750 
and 1750 g. The study compared low-dose (100 mg/kg 
phospholipid) and high-dose (200 mg/kg phospholipid) 
poractant, with beractant, which contains 100 mg/kg of 
phospholipid. The study design was moderately rigorous, 
and participants were exposed to antenatal steroids in at 
least 76% of the sample. The primary outcome was oxygen 
requirement during the first 6 hours after dosing, but 
mortality, need for oxygen at 36 weeks, pneumothorax were 
also recorded. Infants that received the higher initial dose 
of poractant had a survival advantage over those receiving 
beractant, but there was no difference in other clinically 
important outcomes.24
Malloy 2005: This small (n = 60), single center study 
included infants 37 weeks gestation with clinical RDS, 
and randomized infants to receive high dose poractant 
(200 mg/kg) or standard dose beractant (100 mg/kg). The 
study was less rigorous in design, but at least 60% of par-
ticipants were exposed to antenatal steroids. Outcomes 
included overall mortality, BPD at 36 weeks gestation, and 
pneumothorax. There were no differences in major outcomes, 
but infants that received poractant required less oxygen in the 
48 hours after dosing than those receiving beractant.25
Table 2 Summary of ﬁ  ndings of clinical trials comparing animal-derived surfactant preparations used for treatment (rescue) of neonatal 
respiratory distress syndrome
Treatment Beractant vs 
calfactant
Beractant vs 
alveofact
Poractant vs 
beractant
Beractant vs 
colfosceril
Poractant vs 
colfosceril
Poractant vs 
pumactant
Calfactant vs 
colfosceril
Mortality ns ns ns ns ns Poractant ns
O2 requirement ns ns ns ns ns n/a ns
Pneumothorax Calfactant ns ns ns ns n/a Calfactant
Short-term outcomesa Calfactant ns Poractant Beractant Poractant n/a Calfactant
Notes: The contents of the table reﬂ  ect either the favored preparation from head-to-head comparisons, no signiﬁ  cant difference (ns) in outcomes, or inconclusive (n/a).
aweaning mechanical ventilation, short-term oxygen requirement, RDS after dosing with surfactant.
ns, differences not signiﬁ  cant.Therapeutics and Clinical Risk Management 2009:5 255
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In head-to-head comparison trials of poractant vs 
beractant, it appears that poractant has an advantage if the 
higher [initial] dose is used. When used at the higher initial 
dose (200 mg/kg), poractant provides not only more phospho-
lipids but more SP-B than beractant as well (Table 1). Any 
advantage in short-term, physiologic outcomes is presumably 
mediated through the higher content of these surface-active 
agents. It is important to note that these trials were small, and 
larger trials may have demonstrated more striking differences 
(Table 2).20,23–25
Comparisons of animal-derived 
surfactants to synthetic surfactants 
(treatment)
Beractant vs colfosceril palmitate
Horbar 1993: This large (n = 617), multicenter trial, conducted 
between 1991 and 1992, was less rigorous in design than 
recent randomized trials, and included infants between 501 and 
1500 g. This was the ﬁ  rst large scale clinical surfactant trial, and 
only 17% of participants were exposed to antenatal steroids. 
Measured outcomes included death before discharge, clinical 
BPD, and O2 requirement at 36 weeks. Beractant appeared to 
offer a signiﬁ  cant advantage in short-term outcomes, such as 
oxygen requirement and need for ventilatory support, but there 
were no differences in mortality, BPD, or oxygen requirement 
at 36 weeks.26
Sehgal 1994: This small (n = 40), single-center study, 
conducted between 1989 and 1990, included infants whose 
BW was between 600 and 1750 g, and was moderately 
rigorous in design. Exposure to antenatal steroids was not 
reported. Measured outcomes included death and BPD at 
28 days. The beractant group required signiﬁ  cantly less 
ventilatory support, but there was no difference in mortality 
or BPD at 28 days.27
VON trial 1996: This large (n = 1296), multicenter trial, 
conducted between 1992 and 1993, was less rigorous in 
design, and included infants whose BW was between 501 and 
1500 g. Approximately one third of participants were exposed 
to antenatal steroids. Primary outcomes included death before 
discharge, BPD at 28 days and oxygen requirement at 36 weeks 
gestation. Beractant conferred a signiﬁ  cant advantage over 
colfosceril palmitate with regard to oxygen requirement and 
ventilatory support after dosing, as well as fewer air leaks. 
However, there was no signiﬁ  cant difference in mortality, BPD 
at 28 days, or oxygen requirement at 36 weeks gestation.28
Modanlou 1997: This small (n = 122), single center 
study, conducted between 1990 and 1993, was less rigorous 
in design, and included infants whose BW was between 
500 and 1500 g. At least one third of the participants were 
exposed to antenatal steroids. Primary outcomes included 
death and BPD at 28 days. Beractant offered short-term advan-
tages in requirement for oxygen and ventilator weaning, but 
there was no signiﬁ  cant difference in primary outcomes.29
da Costa 1999: This small (n = 89), single center study, 
conducted between 1993 and 1996, was less rigorous 
in design, and included infants 999 g and 37 weeks 
gestation. At least 32% of participants were exposed to 
antenatal steroids. Reported outcomes included death (all 
of which occurred before 28 days), BPD at 28 days, and 
oxygenation index at 24 hours. While the oxygenation 
index at 24 hours was similar between the groups, survanta 
offered a signiﬁ  cant advantage in measures of oxygenation 
(arterial/alveolar oxygen tension). Nonetheless, there were 
no signiﬁ  cant differences in death or BPD at 28 days.30
Clinical trials comparing beractant with colfosceril 
palmitate suggest that beractant appears to have a signiﬁ  cant 
advantage in short-term outcomes, but there is no signiﬁ  cant 
difference in survival or BPD at 36 weeks gestation (Table 2). 
Presumably, the short-term advantages conferred by beractant 
are related to the presence of SP-B and SP-C, which is not 
present in colfosceril palmitate (Table 1). Beractant may also 
derive some of its advantage from the slightly higher dose 
of phospholipid (100 mg/kg) compared to that of colfosceril 
palmitate (67.5 mg/kg) and the presence of variable amounts 
of SP-B.
Poractant vs colfosceril palmitate
Kukkonen 2000: This moderately sized (n = 228), multicenter 
study, conducted between 1994 and 1995, included infants 
with clinical RDS, regardless of gestation or BW. This trial 
was less rigorous in design, but as many as 66% of partici-
pants were exposed to antenatal steroids. Measured outcomes 
included overall mortality, BPD at 36 weeks gestation, and 
pneumothorax. Poractant conferred an advantage in oxygen 
requirement and need for ventilatory support soon after dos-
ing, but these differences normalized with time, and there 
was no signiﬁ  cant difference in stated outcomes. However, 
the colfosceril group appeared to have a slight advantage 
over poractant in survival without BPD. A high rate of cul-
ture-proven sepsis and inﬂ  ammatory markers (eg, C-reactive 
protein) were noted in the poractant group, and while this 
may have adversely impacted outcomes, the sample size was 
too small for further analysis.31
These findings are similar to those of other trials 
comparing natural surfactants to synthetic surfactants that Therapeutics and Clinical Risk Management 2009:5 256
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lack surfactant proteins.5 In general, short-term measures 
of oxygenation and ventilation were better in infants treated 
with poractant (Table 2). The authors suggest that the higher 
incidence of inﬂ  ammatory markers in the poractant group 
was mediated primarily by bacteremia, and review of the 
data supports this conclusion. However, these ﬁ  ndings raise 
important questions regarding the use of animal-derived 
surfactants, which add to the rationale for randomized trials 
that include inﬂ  ammatory markers to the list of important 
outcomes.31
Poractant vs pumactant
Ainsworth 2000: This moderately sized (n = 199) multicenter 
study was conducted between 1989 and 1999, was moderately 
rigorous in design, and included a sample size of 241 infants 
in each group. The study included infants between 25 and 
30 weeks gestation and more than 90% of participants were 
exposed to antenatal steroids. Reported outcomes included 
overall mortality, BPD at 36 weeks gestation, pneumothorax, 
need for respiratory support, and the need for supplemental 
oxygen. The trial was stopped prematurely due to increased 
mortality in the pumactant group. At study closure, there 
was a 60% difference in pre-discharge mortality favoring 
the poractant group. Pumactant (ALEC®, Britannia Pharma-
ceuticals, UK) was withdrawn from the market about 6 years 
ago for this reason.32
There was only one clinical trial comparing poractant with 
pumactant, and the magnitude of the difference in mortality 
was remarkable and not consistent with other comparison 
trials of animal vs synthetic surfactants. Furthermore, it 
seems that this trial had a signiﬁ  cant impact on the systematic 
review of Soll and Blanco, which may have overemphasized 
the beneﬁ  ts of animal-derived surfactants over synthetic 
surfactants (Table 2).5,32
Calfactant vs colfosceril palmitate
Hudak 1996: This large (n = 1133), multicenter study was 
conducted between 1991 and 1993 in 21 neonatal intensive 
care units. The study was rigorous in design, but included 
infants with clinical RDS, regardless of gestation or BW, and 
use of antenatal steroids was not reported. Reported outcomes 
included RDS-related mortality, overall mortality, survival 
without BPD at 28 days, BPD at 36 weeks gestation, and 
incidence of pulmonary air leaks. The calfactant group had a 
slight advantage in gestational age over the colfosceril group, 
otherwise the comparison groups were similar. The calfactant 
group demonstrated a signiﬁ  cant advantage over colfosceril 
palmitate for days in oxygen 30%, duration of mechanical 
ventilation, and incidence of pneumothorax. However, there 
was no signiﬁ  cant difference in overall mortality, mortality 
from RDS, or survival without BPD.33
The calfactant vs colfosceril trial was the only published 
comparison of these surfactants for rescue treatment of 
RDS. Similar to other animal surfactant comparisons with 
ﬁ  rst-generation synthetic surfactants, the calfactant group 
demonstrated a signiﬁ  cant advantage over colfosceril with 
regard to short-term outcomes, presumably due to the pres-
ence of SP-B, but possibly, at least in part, due to the slightly 
higher phospholipid dose as well (Table 1). Nonetheless, 
there were no differences in mortality, mortality from RDS, 
or survival without BPD (Table 2).33
Animal-derived surfactants 
for prevention of RDS (animal-
derived surfactants vs other 
animal-derived surfactants)
Beractant vs calfactant
Bloom 1997: This large (n = 374), multicenter trial, 
conducted between 1992 and 1994, was rigorous in design 
and included both a prevention arm and a treatment arm. The 
prevention arm included infants whose BW was 1250 g. 
Antenatal steroids were given in at least 26% of participants, 
and initial surfactant dosing occurred within 15 minutes of 
delivery. Outcomes measured were mortality at discharge and 
the proportion of infants in oxygen at 36 weeks gestation. 
Dosing with calfactant was associated with a shorter duration 
of supplemental oxygen and mechanical ventilation, but there 
was no difference in mortality or other important neonatal 
outcomes.17
Bloom and Clark 2005: This publication summarizes 
data from two, large multicenter trials, conducted between 
2001 and 2003 (n = 749 infants). The study was rigorous in 
design and included infants whose BW was between 401 
and 2000 g. At least 73% of participants were exposed to 
antenatal steroids and infants received surfactant dosing 
within 10 minutes of delivery. Outcome measures included 
mortality at discharge and the proportion of infants in oxygen 
at 36 weeks gestation. The trial was concluded prematurely 
due to slow enrollment, but at closure there were no differ-
ences in mortality or other neonatal outcomes.19
Comparison of calfactant with beractant for prevention 
of RDS revealed no signiﬁ  cant differences in mortality 
or oxygen requirement at 36 weeks gestation. However, 
infants receiving calfactant were weaned from oxygen and 
from the ventilator quicker than infants receiving beractant. Therapeutics and Clinical Risk Management 2009:5 257
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Once again, the higher concentration of SP-B in calfactant 
is thought to be the factor most likely to contribute to the 
improvements in short-term physiologic outcomes with 
calfactant (Table 3).17,19
Animal-derived surfactants 
compared to synthetic surfactants
Beractant vs lucinactant
Moya 2005: This comparison was intended as a reference 
arm, and was nested in a clinical trial comparing lucinactant 
(Surfaxin®; Discovery Laboratories, Warrington, PA, USA) 
with colfosceril palmitate. The randomization scheme 
included comparisons of lucinactant, colfosceril palmitate, 
and beractant in the ratio 2:2:1. This large (n = 1294), 
multicenter study, conducted between 2001 and 2003, was 
rigorous in design and included infants between 24 and 
32 weeks gestation and between 600 and 1250 g. Antenatal 
steroids were used in at least 74% of participants, and 
surfactant was administered within the ﬁ  rst 30 minutes of life. 
Outcome measures included RDS at 24 hours of life, death 
(related to RDS) at 14 days of life, and the need for supple-
mental oxygen at 28 days and at 36 weeks corrected age.
RDS at 24 hours and RDS-related mortality were signiﬁ  cantly 
reduced in the lucinactant group, and there was a marginally 
signiﬁ  cant reduction in overall mortality (p = 0.051) in the 
lucinactant group as well.34
The only head-to-head comparison of beractant with 
lucinactant for the prevention of RDS suggests that 
lucinactant has a slight advantage in clinically important 
short term outcomes over beractant, including the clinical 
diagnosis of RDS at 24 hours and RDS-related mortality. 
However, there appears to be no difference in air leaks or 
other neonatal morbidities, although overall mortality was 
marginally higher with beractant (Table 3).34
Poractant vs lucinactant
Sinha 2005: This moderately sized (n = 243), multicenter trial, 
conducted between 2001 and 2003, was moderately rigorous 
in design, and was intended as a non-inferiority trial. The 
study included infants between 24 and 28 weeks gestation and 
birthweights between 600 and 1250 g. Outcomes measured 
were death before discharge, survival without BPD, and the 
need for oxygen at 28 days and 36 weeks gestation. Antenatal 
steroids were used in at least 84% of participants. The dose 
of poractant was slightly less than the standard initial dose 
(175 mg/kg), but equivalent to that in lucinactant. There were 
no signiﬁ  cant differences in mortality, survival without BPD, 
need for supplemental oxygen at 36 weeks, or pneumothorax. 
The trial was closed prematurely due to slow enrollment.35
Head-to-head comparisons of lucinactant with both 
poractant and beractant suggest that while lucinactant may have 
a slight advantage, there is no major difference in clinically 
important outcomes between second-generation synthetic 
surfactants and two well-studied natural surfactants.35 The 
non-inferiority of lucinactant to both beractant and poractant 
is an important finding, as exogenously administered 
animal-derived surfactants carry some risk, even if, for now, 
the risks remain theoretical (Table 3).
Calfactant vs colfosceril palmitate
Hudak 1997: This large (n = 871), multicenter study, conducted 
between 1991 and 1993, was rigorous in design and included 
infants 29 weeks gestation. It was intended to detect differ-
ences in 4 clinical outcomes, including the incidence of RDS, 
RDS-related mortality, survival without BPD at 28 days, 
and pulmonary airleaks. Approximately one third of the 
sample received antenatal steroids and most infants received 
surfactant within the ﬁ  rst 30 minutes of life. The incidence of 
RDS and RDS-related mortality was signif icantly reduced in 
Table 3 Summary of ﬁ  ndings of clinical trials comparing animal-derived surfactants used for prevention of neonatal respiratory distress 
syndrome
Prevention Beractant vs 
calfactant
Beractant vs 
lucinactanta
Poractant vs 
lucinactant
Calfactant vs 
colfosceril
Mortality ns ns* ns ns
Oxygen at 36 weeks ns ns ns ns
Pneumothorax ns ns ns ns
Short-term outcomesb Calfactant Lucinactant** Lucinactant Calfactant
Notes: The contents of the table reﬂ  ect either the favored preparation from head-to-head comparisons, or no signiﬁ  cant difference (ns) in stated outcomes.
aBeractant vs lucinactant was nested in trial comparing lucinactant vs colfosceril, and the number of patients in the beractant arm (n = 258) was approximately 50% of the 
lucinactant arm (n = 527).
bweaning mechanical ventilation, short-term oxygen requirement, RDS after dosing with surfactant.
*marginally signiﬁ  cant (p = 0.051) favoring the lucinactant group.
**RDS and/or RDS-related mortality were signiﬁ  cantly decreased in lucinactant group.
ns, differences not signiﬁ  cant.Therapeutics and Clinical Risk Management 2009:5 258
Logan and Moya
infants dosed with calfactant, and infants were weaned more 
rapidly from mechanical ventilation. However, there was 
no difference in overall mortality, BPD or pneumothorax.36 
Analysis of neonatal morbidities revealed that the incidence 
of any IVH (intraventricular hemorrhage) and PVL (periven-
tricular leukomalacia) was higher in the calfactant group.36 
Interestingly, PVL was increased in the calfactant group in 
both clinical trials (treatment and prevention) that compared 
this surfactant with colfosceril palmitate. While some suggest 
this is due to the signiﬁ  cantly higher RDS-related mortality 
noted in the colfosceril palmitate group, a Cochrane meta-
analysis published in 2001, suggests that there was only a 
marginal increase in the risk of any IVH, and no signiﬁ  cant 
effect of calfactant on severe IVH.5
The only published head-to-head comparison of calfactant 
with colfosceril palmitate demonstrated that calfactant had a 
signiﬁ  cant advantage over colfosceril palmitate with regard to 
short-term outcomes, but there was no signiﬁ  cant difference in 
overall mortality, BPD, or pneumothorax. The higher concen-
tration of SP-B found in calfactant is the most likely mediator 
of improvements in short-term outcomes.36 The increase in 
neonatal morbidities (IVH) in the calfactant group may be 
related to the signiﬁ  cantly higher RDS-related mortality in 
the colfosceril palmitate, which by default would select the 
calfactant group for higher neonatal morbidities (Table 3).
Discussion
There is significant heterogeneity between surfactant 
comparison trials, including signiﬁ  cant differences in study 
design. Many were small and lacked a mechanism for blind-
ing providers to the treatment regimen. Furthermore, exposure 
to antenatal steroids, phospholipid and SP-B content, volume 
administered, and pre-speciﬁ  ed outcomes varied substantially 
in many of these trials. Treatment (rescue) trials included 
infants with clinical and/or radiographic RDS, but the BW 
and gestational age criteria varied widely.11 Most of the trials 
summarized here involved treatment of established RDS, 
rather than prophylaxis/prevention (early surfactant), which 
has now become standard practice in many centers. This 
distinction is important, as timing of surfactant administration 
has been reported to impact distribution of surfactant, and a 
Cochrane analysis comparing early (prophylactic) vs delayed 
(rescue) administration of surfactant has shown that early treat-
ment signiﬁ  cantly decreases the incidence of pneumothorax, 
pulmonary interstitial emphysema, chronic lung disease, and 
mortality.37 Additionally, less than half of the protocols included 
pre-speciﬁ  ed guidelines for ventilation and weaning of oxygen, 
an aspect that becomes more important in unblinded trials.
For the most important outcomes, mortality and 
chronic lung disease, currently available animal-derived 
surfactants are similar in efﬁ  cacy. However, for secondary 
outcomes (pneumothorax, ventilator weaning, and need 
for supplemental oxygen), it appears that both calfactant 
and poractant have an advantage over beractant (Tables 2 
and 3). The weight of the evidence, especially with regard 
to study design and secondary outcomes, supports the use 
of calfactant. However, the superiority of poractant over 
beractant, especially when the higher initial dose of poractant 
is used, strengthens the case for use of poractant as well. 
While the size and methodologic quality of the poractant tri-
als were not as rigorous as larger comparison trials involving 
calfactant, the equivalence of animal-derived surfactants 
(with regard to mortality and BPD) and the superiority 
of both calfactant and poractant with regard to secondary 
outcomes, does raise questions over current practice in many 
centers. When combined, the available literature suggests 
that the higher SP-B content in calfactant, and perhaps the 
higher phospholipid content in poractant administered (at 
higher initial dose of phospholipid), are the factors that most 
likely confer the observed advantage of these preparations 
over others.
This summary of clinical trials supports the contention 
that the chief advantage of animal-derived surfactants over 
ﬁ  rst-generation synthetic agents is the presence of surface-
active proteins, especially SP-B. SP-B and SP-C are tightly 
bound to phospholipids and their presence appears to confer 
signiﬁ  cant improvements in surfactant function over products 
that contain only phospholipids.38 It has been suggested that 
lateral stability of the phospholipid monolayer is enhanced 
by the higher content of surfactant proteins in natural 
surfactants.10 Experimental animal studies support this and 
suggest that sufﬁ  cient concentrations of SP-B are necessary to 
promote the function of surface-active phospholipids.38 This 
is also supported by the results of a Cochrane meta-analysis 
comparing animal-derived surfactants with ﬁ  rst-generation 
synthetic surfactants.5 The authors concluded that natural 
surfactants were associated with a signiﬁ  cant reduction in 
mortality, ventilatory requirements, and the incidence of 
pneumothorax when compared to synthetic surfactants that 
lack surfactant proteins.5 When combined, the available 
literature seems to suggest that the advantages conferred by 
animal-derived surfactants are mediated not simply by the 
presence of important surface-active proteins, but by the 
phospholipid content as well.
Finally, second-generation synthetic surfactants also hold 
some promise for the care of infants with neonatal RDS. Therapeutics and Clinical Risk Management 2009:5 259
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A recent update to the Cochrane review of 2001 included the 
addition of two randomized clinical trials comparing a new 
synthetic surfactant, lucinactant (Surfaxin®). Lucinactant 
includes the surfactant protein analog KL-4 (sinapultide), a 
protein moiety that mimics SP-B, and also includes a higher 
dose of phospholipid (175 mg/kg) than both calfactant and 
beractant (Table 1).34,35 The results of the updated Cochrane 
analysis suggest that second-generation synthetic surfactants, 
which contain an SP-B analog, are similar in efﬁ  cacy to 
animal-derived surfactants with regard to prevention of RDS, 
incidence of chronic lung disease, and other complications of 
prematurity.39 Further, the equivalence of second-generation 
synthetic surfactant preparations to the most efﬁ  cacious 
animal-derived products suggests that clinicians and families 
may soon have best-evidence alternatives to currently 
available animal-derived surfactants.
Disclosures
FRM is a paid consultant for Discovery Laboratories, makers 
of lucinactant (Surfaxin®).
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